Source-grounded facts extracted from MAIA Biotechnology, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
MAIA Biotechnology, Inc. shareholders approved Ratification of Auditors at the 2026-05-21 meeting.
“Stockholders ratified the appointment of Grant Thornton LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows: For Against Abstain 37,278,294 210,408 19,052”
MAIA Biotechnology, Inc. shareholders approved Election of Class I Directors at the 2026-05-21 meeting.
“Stockholders re-elected both of the Company’s Class I nominees for director for three-year terms expiring on the annual meeting of stockholders to be held in 2029 or until their successors are duly elected and qualified. Each of the nominees is currently serving as a member of our board of directors. The voting results were as follows: Directors For Withheld Broker Non-Votes Louie Ngar Yee 16,658,677 8,796,832 11,375,414 Steven Chaouki 25,109,811 345,698 11,375,414”
MAIA Biotechnology, Inc. terminated At The Market Offering Agreement with H.C. Wainwright & Co., LLC (effective 2026-05-14).
“On May 14, 2026, MAIA Biotechnology, Inc. (the “Company”) suspended sales of its common stock, par value $0.0001 per share (“Common Stock”), pursuant to that certain At The Market Offering Agreement dated February 14, 2024, or the sales agreement, between the Company and H.C. Wainwright & Co., LLC (the “Agent”), the Company’s sales agent thereunder, and provided notice to the Agent that it is terminating the sales agreement, which termination will be effective 7-business days after May 14, 2026, in accordance with the terms of the sales agreement.”
MAIA Biotechnology, Inc. entered into Underwriting Agreement with Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC valued at approximately $30.0 million (effective 2026-03-02).
“On March 2, 2026, MAIA Biotechnology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC (the “Underwriter”), pursuant to which the Company agreed to issue and sell in an underwritten public offering (the “Offering”) an aggregate of 20,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”).”
MAIA Biotechnology, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at aggregate purchase price of approximately $2,253,896 (effective 2025-12-16).
“On December 16, 2025, MAIA Biotechnology, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”) for the issuance and sale in a private placement (the “ Private Placement ”) of: (i) 1,053,751 shares (the “ Investor Shares ”) of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), and (ii) warrants (the “ Investor Warrants ”) to purchase up to 1,053,751 shares of Common Stock, at a purchase price per Investor Share of $1.224, for an aggregate purchase price of approximately $1,289,792.”
MAIA Biotechnology, Inc. issued 1,053,751 shares of common stock to certain accredited investors for $1.224 per share, aggregate $1,289,792.
“MAIA Biotechnology, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”) for the issuance and sale in a private placement (the “ Private Placement ”) of: (i) 1,053,751 shares (the “ Investor Shares ”) of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), and (ii) warrants (the “ Investor Warrants ”) to purchase up to 1,053,751 shares of Common Stock, at a purchase price per Investor Share of $1.224, for an aggregate purchase price of approximately $1,289,792.”
MAIA Biotechnology, Inc. issued up to 603,769 shares of Common Stock of warrant to certain accredited investors for $1.22 per share.
“MAIA Biotechnology, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”) for the issuance and sale in a private placement (the “ Private Placement ”) of: (i) 603,769_shares (the “ Investor Shares ”) of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), and (ii) warrants (the “ Investor Warrants ”) to purchase up to 603,769 shares of Common Stock, at a purchase price per Investor Share of $1.22, for an aggregate purchase price of approximately $736,600.”
MAIA Biotechnology, Inc. issued 603,769_shares of common stock to certain accredited investors for $1.22 per share.
“MAIA Biotechnology, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”) for the issuance and sale in a private placement (the “ Private Placement ”) of: (i) 603,769_shares (the “ Investor Shares ”) of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), and (ii) warrants (the “ Investor Warrants ”) to purchase up to 603,769 shares of Common Stock, at a purchase price per Investor Share of $1.22, for an aggregate purchase price of approximately $736,600.”
MAIA Biotechnology, Inc. issued 19,230 of warrant to Stan Smith for Issued in conjunction with Director Shares; exercisable at $1.57 per share.
“Investor Shares and 769,230 Investor Warrants for an aggregate purchase price of approximately $1 million. The Investor Warrants are exercisable at a price per Investor Share of $1.57, which price represents the “Minimum Price” as defined under NYSE American Rule 713 on the date the Purchase Agreement was executed (subject to customary adjustments as set”
MAIA Biotechnology, Inc. issued 19,230 of common stock to Stan Smith for $1.30 per share, aggregate approximately $25,000.
“Company director Stan Smith subscribed to purchase 19,230 Director Shares and 19,230 Director Warrants for an aggregate purchase price of approximately $25,000.”
MAIA Biotechnology, Inc. issued 769,230 of warrant to FGMK Business Holdings, LLC for Issued in conjunction with Investor Shares; exercisable at $1.57 per share.
“Investor Shares and 769,230 Investor Warrants for an aggregate purchase price of approximately $1 million. The Investor Warrants are exercisable at a price per Investor Share of $1.57, which price represents the “Minimum Price” as defined under NYSE American Rule 713 on the date the Purchase Agreement was executed (subject to customary adjustments as set”
MAIA Biotechnology, Inc. issued 769,230 of common stock to FGMK Business Holdings, LLC for $1.30 per share, aggregate approximately $1,000,000.
“FGMK Business Holdings, LLC, a greater than 5% holder, subscribed to purchase 769,230 Investor Shares and 769,230 Investor Warrants for an aggregate purchase price of approximately $1 million.”
MAIA Biotechnology, Inc. issued 1,714,536 of warrant to Investors for Issued in conjunction with Investor Shares; exercisable at $1.57 per share.
“The Investor Warrants are exercisable at a price per Investor Share of $1.57, which price represents the "Minimum Price" as defined under NYSE American Rule 713 on the date the Purchase Agreement was executed (subject to customary adjustments as set forth in the Investor Warrants, which do not include any provisions relating to price protection), are exercisable commencing six-months following issuance and have a term of three years from the issuance date.”
MAIA Biotechnology, Inc. issued 1,714,536 of common stock to Investors for $1.30 per share, aggregate $2,228,896.
“MAIA Biotechnology, Inc. (the " Company ") entered into a Securities Purchase Agreement (the " Purchase Agreement ") with certain accredited investors (the " Investors ") for the issuance and sale in a private placement (the " Private Placement ") of: (i) 1,714,536_shares (the " Investor Shares ") of the Company's common stock, par value $0.0001 per share (" Common Stock "), and (ii) warrants (the " Investor Warrants ") to purchase up to 1,714,536 shares of Common Stock, at a purchase price per Investor Share of $1.30, for an aggregate purchase price of approximately $2,228,896.”
MAIA Biotechnology, Inc.: Increased authorized common stock from 70,000,000 to 150,000,000 shares (effective 2025-05-22).
“On May 22, 2025, stockholders of MAIA Biotechnology, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase its authorized common stock from 70,000,000 shares to 150,000,000 shares.”
MAIA Biotechnology, Inc. entered into "Purchase Agreement" with certain accredited investors valued at aggregate purchase price of approximately $664,994 (effective 2024-04-22).
“On April 22, 2024, MAIA Biotechnology, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”) for the issuance and sale in a private placement (the “ Private Placement ”) of: (i) 326,939 shares (the “ Investor Shares ”) of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), and (ii) warrants (the “ Investor Warrants ”) to purchase up to 326,939 shares of Common Stock, at a price per share of $2.034, for an aggregate purchase price of approximately $664,994.”
MAIA Biotechnology, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $1.33 million (effective 2024-03-25).
“On March 25, 2024, MAIA Biotechnology, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”) for the issuance and sale in a private placement (the “ Private Placement ”) of (i) 578,643 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), and (ii) warrants (the “ Warrants ”) to purchase up to 578,643 shares of Common Stock, at a price per share of $2.295, for an aggregate purchase price of approximately $1.33 million.”
MAIA Biotechnology, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $2.4 million (effective 2024-03-11).
“On March 11, 2024, MAIA Biotechnology, Inc. (the " Company ") entered into a Securities Purchase Agreement (the " Purchase Agreement ") with certain accredited investors (the " Investors ") for the issuance and sale in a private placement (the " Private Placement ") of (i) 2,043,587 shares (the "Investor Shares") of the Company’s common stock, par value $0.0001 per share (" Common Stock "), and (ii) warrants (the " Investor Warrants ") to purchase up to 2,043,587 shares of the Company’s Common Stock, at a price per share of $1.17 for an aggregate purchase price of approximately $2.4 million.”
MAIA Biotechnology, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at up to $1,445,000 (effective 2024-02-14).
“On February 14, 2024, MAIA Biotechnology, Inc. (“we,” “us,” the “Company” or “MAIA”) entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), to sell shares of our common stock, par value $0.0001 per share, (the “Shares”) having an aggregate sales price of up to $1,445,000”
MAIA Biotechnology, Inc. entered into Securities Purchase Agreement with three institutional accredited investors valued at gross proceeds of approximately $4.0 million (effective 2023-11-15).
“On November 15, 2023, MAIA Biotechnology, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with three institutional accredited investors (the “Investors”) pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of NYSE American (the “Registered Offering”), 2,424,243 shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”), at a price per Share of $1.65.”
MAIA Biotechnology, Inc. terminated Sales Agreement with ThinkEquity LLC valued at upsize total offering amount of up to $7,000,000; gross proceeds of $1,667,084.40 from sale of 758,3 (effective 2023-11-15).
“On November 15, 2023, MAIA Biotechnology, Inc. (the “Company”) suspended sales of its common stock, par value $0.0001 per share (“Common Stock”), pursuant to that certain Sales Agreement, dated as of September 1, 2023 (the “Sales Agreement”), between the Company and ThinkEquity LLC (the “Agent”), the Company’s sales agent thereunder, and provided notice to the Agent that it is terminating the Sales Agreement, which termination will be effective 10 days after November 15, 2023, in accordance with the terms of the Sales Agreement.”
Jeffrey Himmelreich was appointed as Head of Finance at MAIA Biotechnology, Inc..
“On the same date, the Company appointed Jeffrey Himmelreich as its Head of Finance and principal financial and accounting officer.”
Dr. Mihail Obrocea was terminated as Chief Medical Officer at MAIA Biotechnology, Inc..
“On November 10, 2023, Joseph McGuire and Dr. Mihail Obrocea were terminated from their positions as Chief Financial Officer (and principal financial and accounting officer) and Chief Medical Officer, respectively, of the Company, effective immediately, as part of the Company’s effort to streamline operations.”
Joseph McGuire was terminated as Chief Financial Officer at MAIA Biotechnology, Inc..
“On November 10, 2023, Joseph McGuire and Dr. Mihail Obrocea were terminated from their positions as Chief Financial Officer (and principal financial and accounting officer) and Chief Medical Officer, respectively, of the Company, effective immediately, as part of the Company’s effort to streamline operations.”
MAIA Biotechnology, Inc. reported the third quarter ended September 30, 2023 results: net income Net loss was approximately $4.9 million, or $0.36 per share, for the quarter ended September 30, 2023, EPS $0.36 per share.
“MAIA Biotechnology, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended September 30, 2023”
MAIA Biotechnology, Inc. entered into Sales Agreement with ThinkEquity LLC valued at up to $7,000,000 (effective 2023-09-01).
“On September 1, 2023, MAIA Biotechnology, Inc. (the “Company”), entered into an “at-the-market” Sales Agreement (the “Sales Agreement”) with ThinkEquity LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $7,000,000, subject to the terms and conditions of the Sales Agreement.”
MAIA Biotechnology, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was approximately $4.5 million for the quarter ended June 30, 2023, as compared to net loss of approximately $3.
“MAIA Biotechnology, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended June 30, 2023”
MAIA Biotechnology, Inc. shareholders approved Amendment to the MAIA Biotechnology, Inc. 2021 Equity Incentive Plan to include automatic annual increase in shares reserved at the 2023-05-25 meeting.
“Stockholders approved an amendment to the MAIA Biotechnology, Inc. 2021 Equity Incentive Plan (the “2021 Plan” ) to include an automatic increase in the aggregate number of shares reserved for awards under the 2021 Plan”
MAIA Biotechnology, Inc. shareholders approved Ratification of appointment of Grant Thornton LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-05-25 meeting.
“Stockholders ratified the appointment of Grant Thornton LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023”
MAIA Biotechnology, Inc. shareholders approved Election of Class I directors for three-year terms expiring in 2026 at the 2023-05-25 meeting.
“Stockholders re-elected both of the Company’s Class I nominees for director for three-year terms expiring on the annual meeting of stockholders to be held in 2026 or until their successors are duly elected and qualified”
MAIA Biotechnology, Inc. reported first quarter ended March 31, 2023 results: net income approximately $4.1 million.
“Net loss was approximately $4.1 million for the quarter ended March 31, 2023, as compared to net loss of approximately $3.9 million for the quarter ended March 31, 2022.”
MAIA Biotechnology, Inc. entered into Underwriting Agreement with ThinkEquity LLC valued at aggregate net proceeds of approximately $5.1 million (effective 2023-04-24).
“On April 24, 2023, MAIA Biotechnology, Inc., a Delaware corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with ThinkEquity LLC, as representative (the “Representative”) of the several underwriters identified therein”
MAIA Biotechnology, Inc. reported for the year ended December 31, 2022 results: net income approximately $15.7 million.
“Net loss was approximately $15.7 million for the year ended December 31, 2022, as compared to net loss of approximately $12.6 million for the year ended December 31, 2021.”
Jean-Manassé Theagène was elected as Class III Director at MAIA Biotechnology, Inc..
“On March 17, 2023, upon the recommendation of the Nominating and Corporate Governance Committee (the “Nominating Committee”) of the Board, the Board elected Jean-Manassé Theagène to serve as a Class III director of the Board, with immediate effect, until the Company’s 2025 annual meeting of stockholders, or until such time as he resigns or is removed, and his successor has been elected and qualified.”
Laurentiu Vlad resigned as Class III Director and Audit Committee Member at MAIA Biotechnology, Inc..
“On March 13, 2023, Laurentiu Vlad notified MAIA Biotechnology, Inc. (the “Company”) that he is resigning from the Board of Directors (the “Board”) of the Company effective on March 16, 2023, due to personal reasons.”
MAIA Biotechnology, Inc. reported that prior financial statements should not be relied upon.
“On February 3, 2023, the audit committee (“Audit Committee”) of the board of directors of the Company concluded, after discussion with the Company’s management, that it is appropriate to restate the Company’s previously issued unaudited condensed consolidated balance sheet as of September 30, 2022, the unaudited condensed consolidated statements of operations, unaudited condensed consolidated statements of comprehensive loss and unaudited condensed consolidated statements of stockholders’ equity for the three and nine months ended September 30, 2022, and the unaudited condensed consolidated statement of cash flows for the nine months ended September 30, 2022 included in the Company’s previously filed Quarterly Report on Form 10-Q with the Securities and Exchange Commission (the “Form 10-Q” and, the financial statements included in the Form 10-Q, the “Non-Reliance Financial Statements”).”
MAIA Biotechnology, Inc. engaged Grant Thornton LLP as its auditor.
“On November 21, 2022, upon the approval of the Audit Committee, the Company engaged Grant Thornton LLP ("Grant Thornton") as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022, effective immediately.”
MAIA Biotechnology, Inc. dismissed EisnerAmper LLP as its auditor.
“On November 21, 2022, upon the approval of its Audit Committee of the Board of Directors (the “Audit Committee”) of MAIA Biotechnology , Inc. (the "Company"), the Company dismissed EisnerAmper LLP ("EisnerAmper") as the Company’s independent registered public accounting firm.”
MAIA Biotechnology, Inc. reported third quarter ended September 30, 2022 results: net income Net loss was approximately $3.9 million.
“MAIA Biotechnology Reports Third Quarter 2022 Financial Results”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.